Skip to main content

Test Price

3,000 AED

✅ Home Collection Available

Newborn Genetic Screening Panel (NGS) Test in UAE | 3000 AED | DHA Licensed

Executive Summary & Core Metrics

This newborn genetic screening panel utilises Next Generation Sequencing (NGS) technology to deliver comprehensive coverage of over 100 inborn errors of metabolism and genetic disorders with 99.9% diagnostic sensitivity. Results are available within 3–4 weeks from a single blood sample or FTA card. The test includes telephonic post-test clinical guidance and direct insurance billing verification via WhatsApp.

  • Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
  • Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection — Available daily from 8 AM to 11 PM.
  • Clinical Guidance: Telephonic Post-Test Genetic Counselling included in result interpretation.
  • Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

This NGS-based newborn screening panel analyses DNA from a single blood spot or FTA card to detect pathogenic variants associated with aminoacidopathies, organic acidurias, fatty acid oxidation defects, urea cycle disorders, and lysosomal storage diseases. The assay achieves single-nucleotide resolution and is processed in an ISO-accredited laboratory under strict quality controls.

Feature Our Test (NGS Panel) Standard Newborn Screening (Tandem MS)
Methodology Next Generation Sequencing (NGS) – genome-wide analysis Tandem Mass Spectrometry (MS/MS) – targeted metabolite profiling
Diagnostic Precision 99.9% sensitivity; detects variants at single-nucleotide resolution ~95% sensitivity; limited to predetermined metabolite cutoffs
Turnaround Time 3-4 weeks (comprehensive variant interpretation) 1-2 weeks (biochemical screening only)
Scope of Disorders Over 100 metabolic and genetic disorders, including rare diseases Approximately 30–50 common inborn errors of metabolism
Post‑Test Support Telephonic genetic counselling and clinical guidance included Result report only; counselling often not bundled

Physician Insight & Safety Protocols

Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA Registration ID: 9294403) advises: “As a consultant medical geneticist, I interpret newborn NGS panels within the comprehensive clinical and family context. A positive finding directs targeted confirmatory testing and expedites specialist referral, while a negative result does not exclude all metabolic disorders, particularly if clinical symptoms persist. Genetic counseling is essential before and after testing to ensure informed decision-making and appropriate follow-up.”

Advisory Notice – Medication Safety

⚠️ Important: Do not discontinue or alter any prescribed medication for your infant based solely on genetic screening results. Changes to treatment regimens without physician oversight may precipitate metabolic decompensation or other serious adverse events. Always consult a qualified paediatrician or neonatologist before making any clinical decisions.

Exclusion Criteria & Emergency Red Flags

  • Exclusion Criteria: Infants with a previously confirmed molecular diagnosis for the same condition; critically ill neonates for whom sample collection would delay urgent life‑sustaining treatment.
  • Emergency Red Flags – Seek Immediate Medical Attention: Sudden lethargy, poor feeding, intractable vomiting, seizures, respiratory distress, or hypothermia in a newborn. These may signal an acute metabolic crisis.

Patient FAQ & Clinical Guidance

1. What conditions does this newborn genetic panel screen for?

This NGS panel screens for over 100 metabolic and genetic disorders in newborns, enabling early detection and intervention. Conditions include aminoacidopathies, organic acidurias, fatty acid oxidation defects, urea cycle disorders, and lysosomal storage diseases, all identified through precise DNA sequencing.

2. How is the sample collected for my newborn, and is it safe?

Our VIP mobile phlebotomy team collects a small blood sample from the heel or vein using a sterile, single‑use lancet. The procedure is quick, minimally invasive, and performed by certified paediatric phlebotomists; home collection eliminates hospital stress. Samples can also be applied to a DNA FTA card for easy transport. Collection is available daily from 8 AM to 11 PM.

3. What if the test detects a genetic condition? Will a genetic counsellor help?

A positive result includes a telephonic consultation with a DHA‑licensed genetic counsellor who explains implications, confirmatory testing, and management. Our team coordinates referrals to paediatric metabolic specialists and supports the family through the diagnostic journey, ensuring no parent navigates the results alone.

4. How long does it take to receive the results?

Turnaround time is 3 to 4 weeks from sample receipt. This duration allows for comprehensive sequencing, bioinformatic analysis, variant interpretation, and clinical review by our genetics team to ensure accuracy and reliability of every result.

UAE Regulatory & Data Privacy Adherence

DNA Labs UAE operates in full compliance with UAE federal data protection and healthcare information security frameworks. Patient genetic data is handled under:

  • Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – governing the collection, processing, and storage of personal health information.
  • Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – regulating health data exchange and cybersecurity standards.
  • Federal Decree-Law No. 4 of 2016 on Medical Liability – ensuring clinical safety and informed patient consent for all diagnostic procedures.

All genetic reports are encrypted, access-controlled, and retained only as long as necessary for clinical care and legal compliance.

Clinical & Logistical Metadata

Test Name Newborn Genetic Screening Panel (NGS)
Price (AED) 3,000 AED
Turnaround Time 3–4 weeks
Sample Type / Matrix Peripheral whole blood (heel prick or venipuncture) or FTA card
Methodology Used Next Generation Sequencing (NGS)
ICD-10-CM Code Z13.89
LOINC Code 81247-9
DHA Facility License & Laboratory Address DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians